Peer Reviewed

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment
Phase II
Read more...

Intranasal insulin improves cognition and modulates β-amyloid in early AD
The results of this pilot study support further investigation of the benefits of intranasal insulin for patients with Alzheimer disease, and suggest that intranasal peptide administration may be a novel approach to the treatment of neurodegenerative disorders.
Read more...

Superior deposition in gamma scintigraphy studies
Gamma scintigraphy studies have confirmed Controlled Particle Dispersion's unique ability to saturate the entire nasal cavity, including the olfactory regions and the paranasal sinuses. Read more...

Clinical efficacy in Alzheimer's study
Insulin delivered by ViaNase shows promise for patients with Alzheimer’s and Mild Cognitive Impairment. Read more

Live virus potency maintained in CDC study

Download a technical brochure on Controlled Particle Dispersion


  Home | Nasal Drug Delivery | Technology | Clinical Studies | Devices | Investors | News & Events | About Kurve | Contact

Copyright 2017, Kurve Technology, Inc. All Rights Reserved | Site Map
Technology Marketing